New Website for Cancer Pain Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

NEW YORK-The Association of Cancer Online Resources (ACOR) has launched a new website, Cancer-pain.org, to provide cancer patients with the education and support they need to obtain effective pain relief.

NEW YORK—The Association of Cancer Online Resources (ACOR) has launched a new website, Cancer-pain.org, to provide cancer patients with the education and support they need to obtain effective pain relief.

The site features sections on the causes of pain, breakthrough pain, pain treatment options, and tools to help cancer patients communicate effectively with physicians about their pain. It also has a complete list of medications available to treat pain, information about complementary and alternative methods of pain control, and a section devoted to the special needs and issues of caregivers. The website is supported through an educational grant from Cephalon, Inc.

Articles in this issue
Adjuvant Chemo Dose Reductions Frequent in Breast Cancer
Women May Be at Greater Risk for Undertreatment of Cancer Pain
Umbilical Cord Blood in Adult Leukemia Patients
Irinotecan Results Continue to Be Encouraging in Colorectal Cancer
Irinotecan Active in Pediatric Cancers
Combined Modality Therapy Has Enhanced Activity in Locally Advanced Rectal Cancer
Ultrasound Contrast Agents Help Diagnose Prostate Cancer
Optimal Use of Irinotecan Still to be Determined
Groups Urge Federal Action Against Eclipse Cigarettes
Potential Advantages of Oral Irinotecan Defined in Phase I Studies
New Website for Cancer Pain Patients
Creative Center for Women With Cancer Adds the Performing Arts
More Precise Surrogate Markers for Clinical Response Are Needed
Rubitecan Appears Active in Advanced Pancreatic Cancer
Physicians Must Unite Against New Bureaucratic ‘Hassles’ to Practicing Medicine
Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
3 experts are featured in this series.
3 experts are featured in this series.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
4 experts are featured in this series.
6 experts are featured in this series.
Related Content
Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

CHIP-Carrying Multiple Myeloma Correlates With More Aggressive Disease

Roman Fabbricatore
February 4th 2025
Article

Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.

CHMP Recommends EU Approval for Durvalumab in Limited-Stage SCLC

Roman Fabbricatore
February 4th 2025
Article

Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Ariana Pelosci
February 4th 2025
Article

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Tim Cortese
February 3rd 2025
Article

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.